BerGenBio ASA
BRRGF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.8B
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $3.80 Billion |
|---|---|
| Enterprise Value | $3.69 Billion |
| Earnings per Share | $-125.02 |
| Beta | 1.31 |
| Outstanding Shares | 39,087,116 |
Return
| Return on Equity | -345.68% |
|---|---|
| Return on Assets | -217.36% |
| Return on Invested Capital | -327.23% |
Valuation & Multiples
| P/E Ratio | -0.8 |
|---|---|
| PEG | -3.12 |
| Price to Sales | - |
| Price to Book Ratio | 48.55 |
| Enterprise Value to Revenue | 148.13 |
| Enterprise Value to EBIT | -13.99 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Oncoinvent ASA
44 employees
CEO: Oystein Soug
Oncoinvent ASA is a biopharmaceutical firm dedicated to creating novel therapies for cancer. The company concentrates its efforts on building a diverse range of AXL kinase inhibitors. Its flagship product, bemcentinib, stands out as a hi...